Revenue resilience Trajan reports 2026-27 revenue of $161.4M with EBITDA of $13.2M, indicating a stable but modest growth profile. Sales opportunities could focus on expanding instrument and consumables adoption in existing labs to offset cyclical slowdowns.

Global expansion Operations across Australia, Europe, the US and Asia suggest regional uptake potential. Target multi-region lab networks with HDExaminer PRO and microsampling solutions to standardize workflows across sites.

HDExaminer PRO Product launch of HDExaminer PRO v1.0 signals a move toward workflow integration and native mutant analysis. Upsell opportunities exist for add-ons, service contracts, and training bundles for new users and transitioning labs.

Strategic partnerships Distribution deals with GenTegra and AppMed indicate a channel-led growth model. Leverage these partnerships to access RNA stabilization and microsampling markets in complementary regions and industries.

Growth in healthcare focus Emphasis on portable, miniaturized, and affordable analytical tools aligns with trends toward point-of-care and field diagnostics. Position Trajan’s portable solutions to labs expanding near-patient testing and environmental/food safety monitoring.